checkAd

     1076  0 Kommentare New Data Shows Greater In Vitro Potency for VIBATIV(R) (Telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, Compared to Alternative Antibiotic Treatments

    GEORGE TOWN, GRAND CAYMAN--(Marketwired - Apr 24, 2015) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced new positive data from studies of VIBATIV® (telavancin), the Company's FDA-approved antibiotic. These studies' results will be the focus of presentations at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held over the next several days in Copenhagen, Denmark. 

    Results from these studies demonstrated the in vitro potency for VIBATIV against a broad collection of contemporary clinical pathogens (Staphylococcal and Streptococcal spp.) from hospitals in Europe and surrounding geographic regions during 2012-2013, including methicillin-resistant Staphylococcus aureus (MRSA). The findings demonstrated greater in vitro activity for VIBATIV in difficult-to-treat Gram-positive pathogens as compared to other well-known antibiotics such as vancomycin, daptomycin and linezolid. The potency differences for VIBATIV, as compared to the other antibiotics, were most significant when the target pathogen was categorized as multidrug-resistant (MDR).

    "It is important to appreciate that VIBATIV has shown this activity against real-world bacteria strains that include pathogens, such as MRSA, that are not responding to treatment with a number of antibiotics. It is these difficult-to-treat and MDR bacteria that are at the center of the growing global threat of antibiotic resistance," said Frank Pasqualone, Senior Vice President, Development and Operations at Theravance Biopharma. "By remaining active against pathogens that are non-susceptible to daptomycin and/or resistant to vancomycin, VIBATIV provides clinicians an important antibiotic treatment option for some of their most problematic cases. We believe that this demonstration of greater in vitro potency against these challenging MDR Gram-positive bacteria compared to certain other well-known antibiotics highlights a key difference of VIBATIV in the fight against antibiotic resistance."

    Seite 1 von 7





    Verfasst von Marketwired
    New Data Shows Greater In Vitro Potency for VIBATIV(R) (Telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, Compared to Alternative Antibiotic Treatments GEORGE TOWN, GRAND CAYMAN--(Marketwired - Apr 24, 2015) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced new positive data from studies of VIBATIV® (telavancin), the Company's FDA-approved …